Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sagent Pharmaceuticals, a specialty pharmaceutical company, has launched Ondansetron Injection, USP, an antiemetic, in two latex-free vial presentations.
Subscribe to our email newsletter
Ondansetron Injection, USP is indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and for prevention of postoperative nausea and/or vomiting.
The injection features the company’s PreventIV Measures packaging and labeling, designed to help reduce medication errors.
The US market for Ondansetron Injection, USP for the 12 months ending June 2012 is approximated $49m, according to IMS data.